Morita Yoshinori, Campos Alberto Eduardo, Suzuki Shuichi, Sato Yoshinori, Hoshioka Akira, Abe Hiroki, Saito Kimiyuki, Tsubaki Toshikazu, Haraki Mana, Sawa Akiko, Nakayama Yoshio, Kojima Hiroyuki, Shigeta Midori, Yamaide Fumiya, Kohno Yoichi, Shimojo Naoki
Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba 263-8522, Japan.; Department of Pediatrics, Chiba Kaihin Municipal Hospital, Chiba 261-0012, Japan.
Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba 263-8522, Japan.
Asia Pac Allergy. 2017 Jan;7(1):10-18. doi: 10.5415/apallergy.2017.7.1.10. Epub 2017 Jan 26.
Leukotriene receptor antagonists have been used to prevent virus-induced asthma exacerbations in autumn. Its efficacy, however, might differ with age and sex.
This study aimed to investigate whether pranlukast added to usual asthma therapy in Japanese children during autumn, season associated with the peak of asthma, reduces asthma exacerbations. It was also evaluated the effect of age and sex on pranlukast's efficacy.
A total of 121 asthmatic children aged 1 to 14 years were randomly assigned to receive regular pranlukast or not according to sex, and were divided in 2 age groups, 1-5 years and 6-14 years. The primary outcome was total asthma score calculated during 8 weeks by using a sticker calendar related to the days in which a child experienced a worsening of asthma symptoms. This open study lasted 60 days from September 15 to November 14, 2007.
Significant differences in pranlukast efficacy were observed between sex and age groups. Boys aged 1 to 5 years had the lower total asthma score at 8 weeks ( = 0.002), and experienced fewer cold episodes ( = 0.007). There were no significant differences between pranlukast and control group in total asthma score at 8 weeks ( = 0.35), and in the days in which a child experienced a worsening of asthma symptoms ( = 0.67).
There was a substantial benefit of adding pranlukast to usual therapy in asthmatic children, especially in boys aged 1 to 5 years, during autumn season.
白三烯受体拮抗剂已被用于预防秋季病毒诱发的哮喘加重。然而，其疗效可能因年龄和性别而异。
本研究旨在调查在秋季（与哮喘高峰期相关的季节），在日本儿童的常规哮喘治疗中加用普仑司特是否能减少哮喘加重。同时还评估了年龄和性别对普仑司特疗效的影响。
总共121名1至14岁的哮喘儿童根据性别随机分配接受或不接受常规普仑司特治疗，并分为两个年龄组，1至5岁组和6至14岁组。主要结局是在8周内使用与儿童哮喘症状恶化天数相关的贴纸日历计算的哮喘总分。这项开放性研究从2007年9月15日持续到11月14日，为期60天。
在性别和年龄组之间观察到普仑司特疗效存在显著差异。1至5岁的男孩在8周时哮喘总分较低（P = 0.002），感冒发作次数较少（P = 0.007）。在8周时普仑司特组和对照组在哮喘总分（P = 0.35）以及儿童哮喘症状恶化天数方面（P = 0.67）没有显著差异。
在秋季，在哮喘儿童的常规治疗中加用普仑司特具有显著益处，尤其是在1至5岁的男孩中。
